420 Magazine Background

Loss Of Cannabinoid Receptor CB1 Induces Preterm Birth

420 News

New Member
Haibin Wang,#¤a Huirong Xie,#¤b and Sudhansu K. Dey*¤b
Departments of Pediatrics, Cell & Developmental Biology, and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
Susan J. Fisher, Editor
University of California San Francisco, United States of America
#Contributed equally.
* E-mail: sk.dey@cchmc.org
Conceived and designed the experiments: HW HX SKD. Performed the experiments: HW HX. Analyzed the data: HW HX SKD. Wrote the paper: HW SKD.
¤aCurrent address: State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
¤bCurrent address: Division of Reproductive Sciences, Cincinnati Children's Research Foundation. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America
Received June 23, 2008; Accepted September 8, 2008.
Small right arrow pointing to: This article has been cited by other articles in PMC.

Other Sections▼

Abstract
Background
Preterm birth accounting approximate 10% of pregnancies in women is a tremendous social, clinical and economic burden. However, its underlying causes remain largely unknown. Emerging evidence suggests that endocannabinoid signaling via cannabinoid receptor CB1 play critical roles in multiple early pregnancy events in both animals and humans. Since our previous studies demonstrated that loss of CB1 defers the normal implantation window in mice, we surmised that CB1 deficiency would influence parturition events.
Methods and Findings
Exploiting mouse models with targeted deletion of Cnr1, Cnr2 and Ptgs1 encoding CB1, CB2 and cyclooxygenase-1, respectively, we examined consequences of CB1 or CB2 silencing on the onset of parturition. We observed that genetic or pharmacological inactivation of CB1, but not CB2, induced preterm labor in mice. Radioimmunoassay analysis of circulating levels of ovarian steroid hormones revealed that premature birth resulting from CB1 inactivation is correlated with altered progesterone/estrogen ratios prior to parturition. More strikingly, the phenotypic defects of prolonged pregnancy length and parturition failure in mice missing Ptgs1 were corrected by introducing CB1 deficiency into Ptgs1 null mice. In addition, loss of CB1 resulted in aberrant secretions of corticotrophin-releasing hormone and corticosterone during late gestation. The pathophysiological significance of this altered corticotrophin-releasing hormone-driven endocrine activity in the absence of CB1 was evident from our subsequent findings that a selective corticotrophin-releasing hormone antagonist was able to restore the normal parturition timing in Cnr1 deficient mice. In contrast, wild-type females receiving excessive levels of corticosterone induced preterm birth.
Conclusions
CB1 deficiency altering normal progesterone and estrogen levels induces preterm birth in mice. This defect is independent of prostaglandins produced by cyclooxygenase-1. Moreover, CB1 inactivation resulted in aberrant corticotrophin-releasing hormone and corticosterone activities prior to parturition, suggesting that CB1 regulates labor by interacting with the corticotrophin-releasing hormone-driven endocrine axis.

Other Sections▼

Introduction
Anandamide and 2-arachidonoylglycerol are two major endocannabinoids that activate two G protein-coupled cannabinoid receptors CB1 and CB2, encoded by Cnr1 and Cnr2, respectively [1]—[4]. These endocannabinoids mimic many effects of Δ9-tetrahydrocannabinol (THC), a major psychoactive component of marijuana, on central and peripheral systems [5]—[10]. With respect to female reproduction, we first provided evidence in mice for the presence of CB1 in preimplantation embryos [11], [12] and of anandamide in the oviduct and uterus [12]—[15], suggesting that endocannabinoid signaling is operative during early pregnancy. This was further supported by our findings of biphasic effects of anandamide on embryo development and implantation [16], [17]. For example, anandamide at a low concentration makes the blastocyst competent for implantation, while at a higher concentration it attenuates this response [16]. These observations later led to studies in humans showing an association of higher anandamide levels with spontaneous pregnancy loss [18]. Moreover, we recently found that loss of CB1 often derails oviductal embryo transport, preventing on-time implantation [19]. Since a short delay in on-time implantation adversely affects later developmental processes [20]—[22], we explored the consequences of silencing of CB1 on the onset of labor.
Here we demonstrate that CB1 inactivation in mice induces preterm labor by altering normal progesterone/estrogen ratios prior to parturition. This defect is independent of cyclooxygenase-1 (COX-1)-produced prostaglandins, since loss of CB1 overrides delayed parturition that occurs in Ptgs-1 deficient mice. More strikingly, loss of CB1 resulted in altered corticotrophin-releasing hormone (CRH) and corticosterone (CTS) levels during late gestation, suggesting that CB1 regulates labor by interacting with CRH-CTS endocrine axis. This study has high clinical relevance, since there is evidence that normal onset and duration of labor involve anandamide signaling in women [23], [24] and that CRH is considered as a pregnancy clock controlling pregnancy length in women [25], [26]. This is an issue of concern, since preterm birth accounting approximate 10% of pregnancies in women is a major social, clinical and economic burden [27], [28].

Other Sections▼

Results and Discussion
CB1 deficiency induces preterm labor in mice
Increasing evidence points toward critical roles of endocannabinoid signaling during early pregnancy [8]—[10]. We recently demonstrated that loss of CB1 derails oviductal embryo transport, leading to deferral of on-time embryo implantation [19]. Since an initial deferral of implantation is often associated with delayed parturition [22], we speculated that CB1 deficiency would result in delayed parturition in mice. However, we observed that genetic loss of Cnr1, but not Cnr2, leads to preterm labor (Figure 1A). Consequently, fetal weight at birth in Cnr1−/− mice is significantly reduced compared with wild-type (WT) mice (Figure 1B). In contrast, the parturition events in mice missing Cnr2 are apparently normal (Figure 1A & B).These results may explain why Cnr1−/− pups display poor suckling activities during early days after birth and why their weight gain during postnatal development remains significantly lower than WT control pups [29].
Figure 1

Figure 1
Genetic or pharmacological silencing of CB1 induces preterm labor.
Since Cnr1−/− mice display multiples defects during early pregnancy, including asynchronous preimplantation embryo development [12], impaired oviductal embryo transport and deferred implantation [19], it was not clear whether preterm birth in Cnr1−/− mice was seeded during early pregnancy or resulted from CB1 deficiency during the late gestational period. Therefore, we next examined the consequences of silencing cannabinoid signaling in WT mice by subcutaneous administration of selective CB antagonists during late gestation. As illustrated in Figure 1C & D, similar preterm parturition occurred in WT mice receiving a CB1-selective antagonist SR141716 (SR1) [30], but not a CB2-selective antagonist SR144528 (SR2) [31], on days 14—18 of pregnancy. These observations suggest that endocannabinoid signaling via CB1 is critical to normal gestational length.
The initiation of parturition results from a synchronous interplay of both maternal and fetal factors [28]. Thus, we assessed the contribution of maternal versus embryonic CB1 to parturition defects in Cnr1−/− mice by mating null females with wild-type males to generate all heterozygous embryos. We observed that preterm labor phenotype was sustained in pregnant Cnr1−/− females bearing heterozygous embryos, although birth weights of heterozygous pups were comparable to those of wild-type pups at birth (Figure S1A & B). The results indicate that maternal CB1 signaling is critical for timely onset of labor.
CB1 deficiency alters normal progesterone and estrogen secretions prior to parturition in mice
Recent evidence suggests the involvement of endocannabinoid signaling via central CB1 in neuroendocrine regulation of reproduction. For example, both exogenous cannabinoids and endocannabinoids have been shown to modulate the secretion of hypothalamic and pituitary hormones including luteinizing hormone and prolactin in rodents [32]—[36]. To reveal potential causes of preterm birth in the absence of CB1 in mice, we first examined the expression of CB1 in the hypothalamus and ovary. As illustrated in Figure 2A & B, we observed a wide distribution of CB1 in these tissues on day 18 of pregnancy, suggesting the contention that endocannabinoids would impact the hypothalamic-ovarian axis at multiple levels during late gestation. Since functional progesterone (P4) withdrawal either due to fall in circulating P4 levels or attenuation of P4 action together with heightened estrogen action determines the parturition timing in most viviparous species including humans [37], we measured serum levels of P4 and 17β-estradiol (E2) in Cnr1−/− females during late gestation to assess potential causes of preterm labor in the absence of CB1. As shown in Figure 3A, CB1 deficiency induced an early drop in serum P4 levels on day 19 of pregnancy. In contrast, circulating E2 levels substantially increased on days 16—18 with the loss of CB1 (Figure 3B). This inverse relationship between P4 and E2 levels in the absence of CB1 creates a significant decrease in P4/E2 ratio (Figure 3C), leading to preterm birth in Cnr1−/− females.
Figure 2

Figure 2
Expression of CB1 transcript and protein in the wild-type (WT) brain (A) and ovary (B) on day 18 of pregnancy.
Figure 3

Figure 3
CB1 deficiency alters normal progesterone (P4) and estradiol-17β (E2) levels prior to parturition in mice.
Western blotting analysis of key steroid biosynthetic and metabolic enzymes demonstrated that while levels of cytochrome P450 cholesterol side-chain cleavage enzyme and 3β-hydroxysteroid dehydrogenase (3β-HSD) were comparable in wild-type and Cnr1 null ovaries (data not shown), levels of cytochrome P450 aromatase (P450Arom) and 17β-HSD7, which primarily contribute to ovarian E2 biosynthesis during gestation in mice [38], were upregulated in Cnr1−/− ovaries (Figure 4). Moreover, levels of 20α-HSD, which metabolizes P4 into biologically inactive 20α-dihydroprogesterone, were substantially increased in Cnr1−/− ovaries on day 19 of pregnancy as opposed to that occurs in WT ovaries on day 20 (Figure 4). These temporal changes in P4 metabolic and estrogen biosynthetic enzymes in null ovaries correlate well with our finding of early fall in P4 with rising E2 levels preceding early onset of parturition. As shown in Figure S2A & B, our observation of restoration of normal parturition in Cnr1−/− mice by a subcutaneous injection of P4 (1 mg/mouse) on day 18 further supports that a decreased P4/E2 ratio is a cause of preterm labor in null females. With respect to contribution of gonadotropins and prolactin on this altered ovarian P4 and E2 secretion pattern in the absence of CB1, similar circulating levels of luteinizing hormone were observed in WT and Cnr1−/− mice on days 14—18 of pregnancy. However, basal levels of follicle stimulating hormone substantially increased in Cnr1−/− mice (data not shown). Placenta-derived prolactin-like hormones, but not pituitary prolactin, primarily act to maintain luteal P4 secretion during late gestation in mice [38], [39]. Nonetheless, it would be interesting to see in future studies whether CB1 deficiency alters prolactin secretion at various stages of pregnancy.
Figure 4

Figure 4
Western blot analysis of cytochrome P450 aromatase (P450Arom), 17β-hydroxysteroid dehydrogenase 7 (17β-HSD7) and 20α-HSD in wild-type (WT) and Cnr1−/− ovaries during late gestation.
Loss of CB1 overrides delayed parturition that occurs in cyclooxygenase-1 deficient mice
In mice, genetic ablation of Ptgs1, encoding cyclooxygenase (COX)-1, results in delayed or failure of parturition because of impaired luteolysis with sustained P4 production [40], [41]. To confirm our finding that early decline in serum P4 levels is a trigger for preterm birth in Cnr1−/− mice, we introduced CB1 deficiency into Ptgs1−/− mice to examine their parturition status. It was exciting to see that the loss of CB1 overrides COX-1 deficiency-induced delayed parturition (Figure 5A) and remarkably improves the survival rate of newborn pups (Figure 5B). Similar observations were also noted in pregnant Ptgs1−/− mice receiving SR1, but not SR2, on days 14—18 (Figure 5C & D). These results suggest that CB1 signaling has a unique role in regulating normal parturition that is independent of COX-1-derived prostaglandin F2α, but CB1 deficiency can correct the effects produced by COX-1 deficiency. Recent evidence suggests that cyclooxygenases participate in oxidative metabolism of endocannabinoids, owing to their structural similarity to polyunsaturated fatty acids. For example, both anandamide and 2-arachidonoylglycerol can serve as substrates for COX-2 [42]—[44], and COX-1 [45] in the context of cell types and conditions. Moreover, there is evidence that endocannabinoids via CB1 can upregulate COX-2 expression and thus prostaglandin E2 production in human gestational membranes during late pregnancy [46]. It remains to be determined whether COX-1 deficiency induced delayed parturition is associated with aberrant cannabinoid-CB1 signaling in mice.
Figure 5

Figure 5
Loss of CB1 overrides delayed parturition that occurs in Ptgs1−/− mice.
CB1 deficiency induces aberrant CRH-driven endocrine activities leading to preterm labor in mice
Increasing evidence suggests that the endocannabinoid system influences the secretion of CRH [47], [48], which serves as a clock regulating the length of human pregnancy [25], [26]. To further reveal underlying causes of preterm birth in Cnr1−/− mice, we examined the status of CRH levels during late pregnancy. As illustrated in Figure 6A, while circulating CRH levels peaked on day 19 of pregnancy proceeding the day of labor onset in WT females, an aberrant CRH secretion pattern was noted in mutant females; the levels showed an early rise on day 14 and thereafter remained steady through day 20 in Cnr1−/− females. This early rise in CRH levels in peripheral circulation could be due to dysregulation of the hypothalamus-adrenal axis with an enhanced circadian drive on this stress-related axis in Cnr1−/− mice as previously demonstrated [49]. In fact, we observed significant increases in circulating corticosterone (CTS) levels on days 14—16 of pregnancy in mutant females compared with WT females (Figure 6B). These observations collectively point toward the concept that CB1 signaling is crucial for maintaining normal CRH-CTS activities prior to the onset of parturition in mice.
Figure 6

Figure 6
Aberrant levels of CRH and corticosterone from CB1 deficiency contribute to preterm birth in mice.
Moreover, as seen for CB1 (Figure 2B), immunostaining showed the presence of CRH and its type I receptor (CRH-RI) in WT day 18 corpora lutea (Figure S3), suggesting potential interactions of CB1 and CRH signaling within the ovary prior to parturition. In fact, we noted an early induction of ovarian CRH expression in Cnr1−/− mice with preterm labor (Figure 6C), further supporting that an altered CRH activity is one cause of preterm birth in mice missing CB1. Since there is evidence that CRH interferes with hypothalamic-pituitary-gonadal axis function by acting directly at the ovarian level [50], [51], we speculate that CB1 deficiency-induced aberrant CRH signaling is a potential cause of abnormal P4 and E2 secretion in Cnr1−/− ovary. However, it is to be noted that while the ovary as the primary site of P4 synthesis in pregnant mice contributes to CRH secretion, CRH like P4 is mainly produced by the placenta during late gestation in humans [47]. Regardless of the site of origin of CRH in various species, the physiological relevance of CRH-CTS axis in the onset of normal labor in mice is further supported by our observations that Antalarmin hydrochloride (AH), a CRH-RI selective antagonist, restored normal parturition in Cnr1−/− mice with little effects on fetal birth weights when females were treated on days 15—17 of pregnancy (Figure 7A & B). In contrast, elevated levels of CTS imposed by exogenous administration induced preterm birth with reduced fetal weights in WT females (Figure 7C & D), similar to labor defects in Cnr1−/− mice.
Figure 7

Figure 7
Pharmacological silencing of CRH activities by Antalarmin hydrochloride (AH) on days 15—17 restores normal labor in Cnr1−/− mice with little effects on fetal birth weights (A & B), while enhanced corticosterone (CTS) activity (more ...)
Collectively, we provide here multiple lines of evidence that signaling via CB1 is crucial for the normal onset of labor; its absence induces preterm birth via altering ovarian steroid synthesis and degradation, and CRH-CTS activities. These novel findings have high clinical relevance, since increases in circulating levels of anandamide are associated with labor onset and duration in women [23] and that CRH controls the length of human pregnancy [25], [26]. This is especially a concern in the light of little change in high preterm birth rates during the past 30 years [27], [28], and the use of a selective CB1 antagonist in Europe as an anti-obesity drug [52], [53]. There is evidence that polymorphism of the Cnr1 gene occurs in humans [54] and is associated with variable drug dependency [55]. It remains to be seen whether preterm labor in women is associated with Cnr1 gene polymorphism or mutation.

Other Sections▼

Materials and Methods
Animal models
All experiments were conducted in accordance with National Institutes of Health guidelines and were approved by the Intuitional Animal Care and Use Committee. Cnr1, Cnr2 and Ptgs1 mutant mice on C57BL/6J/129 mixed genetic background were generated as previously described [41], [56], [57]. Cnr1−/− and Ptgs1−/− mice were cross-bred to generate Cnr1−/−/Ptgs1−/− double null mice. Females were mated with fertile males of the same strain to induce pregnancy. The presence of a vaginal plug was considered day 1 of pregnancy. Parturition events were monitored on days 19—21. The time of parturition was defined as complete delivery of pups.
In vivo delivery of drugs
To explore the consequences of pharmacological silencing of CB1 receptors on the onset of parturition, pregnant females received daily subcutaneous administration of SR141716, a CB1 selective antagonist or SR144528, a CB2 selective antagonist at a dose of each 10 mg/Kg·BW, respectively on days 14—18 of pregnancy. To examine the effects of neutralizing CRH activities on the onset of labor, pregnant mice were treated daily with a CRH type I receptor selective antagonist Antalarmin hydrochloride at a dose of 25 mg/Kg·BW via subcutaneous injections on days 15—17. Pregnant wild-type mice treated with corticosterone at a dose of 40 mg/Kg·BW via subcutaneous injections on days 14—18 were examined to see the effects of enhanced corticosterone activity on parturition events. While SR141716 and SR144528 were obtained from National Institute on Drug Abuse, Antalarmin hydrochloride and corticosterone were obtained from Sigma. Drugs were dissolved in Triolein/ethanol (4[ratio]1). Gestation length was measured by monitoring the parturition status on days 19—21.
In situ hybridization
In situ hybridization of Cnr1 in the brain was performed as previously described [58]. Briefly, frozen sections (10 µm) were mounted onto poly-L-lysine-coated slides and fixed in 4% paraformaldehyde solution in PBS at 4°C. After prehybridization, sections were hybridized at 45°C for 4 h in 50% formamide buffer containing 35S-labeled sense or antisense cRNA probes. After hybridization, sections were incubated with RNase A (20 µg/ml) at 37°C for 20 min, and RNase A-resistant hybrids were detected by autoradiography using Kodak NTB-2 liquid emulsion. Sections were poststained with hematoxylin and eosin. Sections hybridized with a sense probe did not show any positive signals and served as controls.
Immunohistochemistry
Immunolocalization of CB1 in the pituitary, ovary and uterus were performed in formalin-fixed paraffin embedded sections using specific antibodies to CB1 receptor (Santa Cruz). A Histostain-Plus (DAB) kit (Invitrogen) was used to visualize the antigen.
Assay P4, E2, corticosterone and CRH
Blood samples from WT and Cnr1−/−mice were collected on days 14—21 of pregnancy. Serum was separated by centrifugation (3,000 rpm for 15 min) and stored at −80°C until assayed. P4, E2, corticosterone levels were measured by radioimmunoassay by the UVA Center for Research in Reproduction Ligand Assay and Analysis Core. CRH was analyzed using an Enzyme Immuno Assay (EIA) kit purchased from Phoenix Pharmaceuticals INC following the manufacture's protocol.
Statistical analyses
Data are expressed as means±s.e.m. Statistical comparisons between two experimental groups were determined by Student's t-test. A P value of less than 0.05 is considered significantly different.

Other Sections▼

Supporting Information
Figure S1
Inter-crossing of Cnr1−/− females with wild-type (WT) males fails to correct preterm labor phenotype in Cnr1−/− females bearing heterozygous embryos (A), although fetal weights of heterozygous embryos were comparable to those of WT at birth (B). Data are means±SEM. Numbers within bars in panel (A) indicate the number of mice examined. The average fetal weights (mg) are shown in panel B. The bars with different letters are significantly different (Student t-test, P<0.01).
(1.35 MB TIF)
Click here for additional data file.(1.2M, tif)
Figure S2
A single subcutaneous injection of progesterone (P4, 1 mg/mouse) on day 18 of pregnancy restores normal parturition (A) and fetal development at term (B) in Cnr1−/− mice. Mice receiving the same volume of sesame oil served as controls. Data are means±SEM. Numbers within bars in panel (A) indicate the number of mice examined. The average fetal weights (mg) are shown in panel B. The bars with different letters are significantly different (Student t-test, P<0.01).
(2.62 MB TIF)
Click here for additional data file.(2.4M, tif)
Figure S3
Immunolocalization of CRH and CRH-RI in WT pregnant day 18 ovaries. Bar, 100 µm. CL, corpus luteum; f, follicle; Hip: hippocampus; o, oocyte.
(3.44 MB TIF)
Click here for additional data file.(3.2M, tif)
Acknowledgments
We are grateful to Geula Gibori and J. Ian Mason for generous gifts of 17β-HSD7, 20α-HSD, and 3β-HSD antibodies.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported in parts by US National Institutes of Health (NIH) Grants DA06668, HD12304 & CA77839 to SKD, and HD050315 to HW. SKD is recipient of Method to Extend Research in Time (MERIT) Awards from the National Institute on Drug Abuse (NIDA) and the National Institute of Child Health and Human Development (NICHD).

Other Sections▼

References
1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561—564. [PubMed]
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61—65. [PubMed]
3. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946—1949. [PubMed]
4. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89—97. [PubMed]
5. Maccarrone M, Finazzi-Agro A. Endocannabinoids and their actions. Vitam Horm. 2002;65:225—255. [PubMed]
6. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873—884. [PubMed]
7. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004;141:765—774. [PMC free article] [PubMed]
8. Wang H, Dey SK, Maccarrone M. Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. Endocr Rev. 2006;27:427—448. [PubMed]
9. Fride E, Shohami E. The endocannabinoid system: function in survival of the embryo, the newborn and the neuron. Neuroreport. 2002;13:1833—1841. [PubMed]
10. Taylor AH, Ang C, Bell SC, Konje JC. The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Hum Reprod Update. 2007;13:501—513. [PubMed]
11. Paria BC, Das SK, Dey SK. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci U S A. 1995;92:9460—9464. [PMC free article] [PubMed]
12. Paria BC, Song H, Wang X, Schmid PC, Krebsbach RJ, et al. Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J Biol Chem. 2001;276:20523—20528. [PubMed]
13. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci U S A. 1995;92:4332—4336. [PMC free article] [PubMed]
14. Schmid PC, Paria BC, Krebsbach RJ, Schmid HH, Dey SK. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A. 1997;94:4188—4192. [PMC free article] [PubMed]
15. Guo Y, Wang H, Okamoto Y, Ueda N, Kingsley PJ, et al. N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. J Biol Chem. 2005;280:23429—23432. [PubMed]
16. Wang H, Matsumoto H, Guo Y, Paria BC, Roberts RL, et al. Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc Natl Acad Sci U S A. 2003;100:14914—14919. [PMC free article] [PubMed]
17. Wang J, Paria BC, Dey SK, Armant DR. Stage-specific excitation of cannabinoid receptor exhibits differential effects on mouse embryonic development. Biol Reprod. 1999;60:839—844. [PubMed]
18. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, et al. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet. 2000;355:1326—1329. [PubMed]
19. Wang H, Guo Y, Wang D, Kingsley PJ, Marnett LJ, et al. Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med. 2004;10:1074—1080. [PubMed]
20. Dey SK. Reproductive biology: fatty link to fertility. Nature. 2005;435:34—35. [PubMed]
21. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature. 2005;435:104—108. [PMC free article] [PubMed]
22. Song H, Lim H, Paria BC, Matsumoto H, Swift LL, et al. Cytosolic phospholipase A2alpha is crucial for 'on-time' embryo implantation that directs subsequent development. Development. 2002;129:2879—2889. [PubMed]
23. Habayeb OM, Taylor AH, Evans MD, Cooke MS, Taylor DJ, et al. Plasma levels of the endocannabinoid anandamide in women—a potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab. 2004;89:5482—5487. [PubMed]
24. Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, et al. Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol. 2004;190:2—9. discussion 3A. [PubMed]
25. McLean M, Bisits A, Davies J, Woods R, Lowry P, et al. A placental clock controlling the length of human pregnancy. Nat Med. 1995;1:460—463. [PubMed]
26. Karalis K, Goodwin G, Majzoub JA. Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat Med. 1996;2:556—560. [PubMed]
27. Smith R. Parturition. N Engl J Med. 2007;356:271—283. [PubMed]
28. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000;21:514—550. [PubMed]
29. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol. 2003;461:27—34. [PubMed]
30. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240—244. [PubMed]
31. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998;284:644—650. [PubMed]
32. Steger RW, Silverman AY, Johns A, Asch RH. Interactions of cocaine and delta 9-tetrahydrocannabinol with the hypothalamic-hypophysial axis of the female rat. Fertil Steril. 1981;35:567—572. [PubMed]
33. Field E, Tyrey L. Tolerance to the luteinizing hormone and prolactin suppressive effects of delta-9-tetrahydrocannabinol develops during chronic prepubertal treatment of female rats. J Pharmacol Exp Ther. 1986;238:1034—1038. [PubMed]
34. Scorticati C, Fernandez-Solari J, De Laurentiis A, Mohn C, Prestifilippo JP, et al. The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci U S A. 2004;101:11891—11896. [PMC free article] [PubMed]
35. Fernandez-Ruiz JJ, Munoz RM, Romero J, Villanua MA, Makriyannis A, et al. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem Pharmacol. 1997;53:1919—1927. [PubMed]
36. Gammon CM, Freeman GM, Jr, Xie W, Petersen SL, Wetsel WC. Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology. 2005;146:4491—4499. [PMC free article] [PubMed]
37. Mesiano S, Welsh TN. Steroid hormone control of myometrial contractility and parturition. Semin Cell Dev Biol. 2007;18:321—331. [PubMed]
38. Stocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, function, and regression. Endocr Rev. 2007;28:117—149. [PubMed]
39. Linzer DI, Fisher SJ. The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. Mol Endocrinol. 1999;13:837—840. [PubMed]
40. Gross GA, Imamura T, Luedke C, Vogt SK, Olson LM, et al. Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. Proc Natl Acad Sci U S A. 1998;95:11875—11879. [PMC free article] [PubMed]
41. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483—492. [PubMed]
42. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997;272:21181—21186. [PubMed]
43. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877—44885. [PubMed]
44. Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem. 2000;275:33744—33749. [PubMed]
45. Rouzer CA, Tranguch S, Wang H, Zhang H, Dey SK, et al. Zymosan-induced glycerylprostaglandin and prostaglandin synthesis in resident peritoneal macrophages: roles of cyclooxygenases-1 and -2. Biochem J 2006
46. Mitchell MD, Sato TA, Wang A, Keelan JA, Ponnampalam AP, et al. Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. Am J Physiol Endocrinol Metab. 2008;294:E352—356. [PubMed]
47. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423—431. [PMC free article] [PubMed]
48. Bayatti N, Hermann H, Lutz B, Behl C. Corticotropin-releasing hormone-mediated induction of intracellular signaling pathways and brain-derived neurotrophic factor expression is inhibited by the activation of the endocannabinoid system. Endocrinology. 2005;146:1205—1213. [PubMed]
49. Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology. 2007;148:1574—1581. [PubMed]
50. Calogero AE, Burrello N, Negri-Cesi P, Papale L, Palumbo MA, et al. Effects of corticotropin-releasing hormone on ovarian estrogen production in vitro. Endocrinology. 1996;137:4161—4166. [PubMed]
51. Mastorakos G, Webster EL, Friedman TC, Chrousos GP. Immunoreactive corticotropin-releasing hormone and its binding sites in the rat ovary. J Clin Invest. 1993;92:961—968. [PMC free article] [PubMed]
52. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121—2134. [PubMed]
53. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389—1397. [PubMed]
54. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes. 1999;13:321—323. [PubMed]
55. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry. 1997;2:161—168. [PubMed]
56. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96:5780—5785. [PMC free article] [PubMed]
57. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A. 1999;96:14136—14141. [PMC free article] [PubMed]
58. Das SK, Wang XN, Paria BC, Damm D, Abraham JA, et al. Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation. Development. 1994;120:1071—1083. [PubMed]


Source: Loss of Cannabinoid Receptor CB1 Induces Preterm Birth
 
Top Bottom